Antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV transmission was first
approved by the US Food and Drug Administration in 2012. Despite correlations of …

Injection drug use is a key risk factor for the transmission of HIV. Prevention strategies, such
as the use of pre-exposure prophylaxis (PrEP), are effective at reducing the risk of HIV …

Diagnoses of HIV among people who inject drugs have increased in the US during 2014–
2018 for the first time in 2 decades, and multiple HIV outbreaks have been detected among …

Clinical trials have demonstrated that preexposure prophylaxis (PrEP) protects against HIV
infection; yet, even with its approval by the Food and Drug Administration (FDA) in 2012 …

Oral HIV pre-exposure prophylaxis (PrEP) is a highly effective pill that HIV-negative
individuals can take once daily to prevent HIV infection. Although PrEP is a private, user …

Introduction A recent surge in HIV outbreaks, driven by the opioid and stimulant use crises,
has destabilized our progress toward targets set forth by Ending the HIV Epidemic: A Plan …

HIV prevalence among cisgender female sex workers (FSW) and/or women who use drugs
(WWUD) is substantially higher compared to similarly aged women. Consistent with PRISMA …

Pre-exposure prophylaxis (PrEP) uptake among women in the United States has been low.
To increase uptake, we developed a peer outreach and navigation PrEP intervention. Semi …

Pre-exposure prophylaxis (PrEP) uptake remains woefully low among US women at high
risk for HIV acquisition. We evaluated a pilot intervention which involved Peers providing …

Background People who inject drugs (PWID) are at an increased risk for HIV infection due to
injection and sexual risk behaviors. This study aims to examine PrEP knowledge …